BALAXI

Balaxi Pharmaceuticals Ltd.

NSE: BALAXI

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

22.77+0.4 (+1.92%)

5 Oct, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

7.1 / 100

Value Score

73.7 / 100

Price Momentum Score

24.7 / 100

QVM Score

18.5 / 100

Key Metrics

Market Cap

125.71

P/E (TTM)

51.86

P/B

0.50

P/S (TTM)

0.45

EV/EBITDA

18.67

CAPE (5Y)

5.68

ROE (TTM)

0.59

ROCE (TTM)

2.15

ROA (TTM)

0.44

Avg 3Y ROE

3.64

Earnings 3Y CAGR

-69.41

Sales 3Y CAGR

-4.30

Sales 5Y CAGR

3.35

Debt/Equity

0.23

Consensus TP

Strong Buy %

Promoter Holding

65.99

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Balaxi Pharmaceuticals Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.23 as on 30 Jun 2026 and Debt to Equity remained same in the last 1 year

What is Debt to Equity?

Negative

Expensive and at a premium to industry median P/E

PE TTM of 51.86 indicates that the stock is expensive on a standalone basis and is at a 64.95% premium to industry median P/E

What is P/E Ratio?

Median: 31.44

Value 51.86

-0.84721.21

Weak price momentum

Price Momentum score of 24.7 indicates that the stock has weak price momentum. Research has shown that stocks with lower momentum continue to underperform in the near term

What is Price Momentum score?

24.7 / 100

Low and declining ROE

The company reported low ROE of 0.59% for 12-month ended 30 Jun 2026 and ROE declined by -1098 bps from 1 year ago

What is ROE (FY)?

Low and declining operating margin

The company reported low operating margin of 2.36% for 12-month ended 30 Jun 2026 and operating margin declined by -751 bps from 1 year ago

What is Operating profit margin?

Low revenue growth and lower than median growth of industry

The company delivered moderate revenue growth of -5.9% for 12-month ended 30 Jun 2026 and the growth was 16.58 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 10.68

Value -5.9

-99.6111701.8

Low EPS growth and lower than median growth of industry

The company delivered moderate EPS growth of -87.08% for 12-month ended 30 Jun 2026 and the growth was 94.53 percentage points lower than median growth of industry

What is EPS growth (1Y)?

Low dividend yield

The company has a low dividend yield of 0.0%

What is Dividend yield?

Neutral

Company's earnings are of moderate quality

Earnings quality score of 31.2 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

31.2 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Balaxi Pharmaceuticals Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Balaxi Pharmaceuticals Ltd. Shareholding Pattern

Quarterly breakdown of Balaxi Pharmaceuticals Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	72.86	72.86	72.86	72.86	72.86	72.86	72.86	72.86	72.86	72.86	72.86	72.69	71.57	71.22	71.22	71.22	66.86	65.99	65.99	65.99	65.99	65.99	65.99	65.99	65.99	65.99
Indian Promoter	72.86	72.86	72.86	72.86	72.86	72.86	72.86	72.86	72.86	72.86	72.86	72.69	71.57	71.22	71.22	71.22	66.86	65.99	65.99	65.99	65.99	65.99	65.99	65.99	65.99	65.99
Foreign Promoter	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	19.04	19.03	19.48	19.48	19.48	19.48	19.48	19.48	19.31	19.03	19.03	18.98	18.69	18.61	18.60	18.60	17.23	16.90	16.50	16.50	16.04	8.89	3.52	1.76	2.56	2.56
Mutual Funds / UTI	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FI/Bank/Insurance	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
Govt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	19.01	19.00	19.45	19.45	19.45	19.45	19.45	19.45	19.28	19.00	19.00	18.95	18.66	18.58	18.58	18.58	17.21	16.88	16.48	16.48	16.02	8.86	3.50	1.74	0.00	0.00
Other Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.54	2.54
Non-Institution	8.09	8.11	7.67	7.65	7.66	7.66	7.65	7.66	7.83	8.11	8.11	8.33	9.75	10.18	10.18	10.18	15.91	17.11	17.49	17.51	17.96	25.12	30.49	32.25	31.45	31.45
Bodies Corporate	0.16	0.19	0.42	0.39	0.36	0.39	0.41	0.40	0.39	0.37	0.19	0.21	0.62	0.50	0.49	0.47	4.11	3.87	3.68	3.19	3.58	4.20	5.16	4.28	0.73	0.77
Others (incl. Retail) No. of shareholders	7.93 568	7.92 592	7.25 1,671	7.26 1,925	7.30 2,613	7.27 3,270	7.24 4,114	7.26 3,842	7.44 3,958	7.74 4,149	7.92 4,773	8.12 4,701	9.13 4,828	9.68 5,088	9.69 5,013	9.71 5,011	11.80 5,156	13.24 6,538	13.81 7,809	14.32 8,473	14.38 9,943	20.92 13,676	25.33 14,552	27.97 15,015	30.72 15,120	30.68 14,632

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Balaxi Pharmaceuticals Ltd. shares as reported to NSE and BSE.

Name	Date	Type	Price	Qty.	Value
RGSL INVESTMENT LVF 1	24 Mar 2026	buy	₹ 17.68	5.22 lac	₹ 92.35 lac
RGSL INVESTMENT LVF 1	23 Mar 2026	buy	₹ 17.24	5.20 lac	₹ 89.68 lac
MITHUN KHAITAN	31 Dec 2025	buy	₹ 27.62	4.20 lac	₹ 1.16 cr
DULCET ADVISORY PRIVATE LIMITED	12 Dec 2025	sell	₹ 31.82	3.31 lac	₹ 1.05 cr
DULCET ADVISORY PRIVATE LIMITED	12 Dec 2025	buy	₹ 30.00	4.71 lac	₹ 1.41 cr
DULCET ADVISORY PRIVATE LIMITED	10 Jul 2025	sell	₹ 50.32	4.94 k	₹ 2.49 lac
DULCET ADVISORY PRIVATE LIMITED	10 Jul 2025	buy	₹ 50.02	2.92 lac	₹ 1.46 cr
DULCET ADVISORY PRIVATE LIMITED	01 Jul 2025	buy	₹ 50.00	3.20 lac	₹ 1.60 cr
EBISU GLOBAL OPPORTUNITIES FUND LIMITED	04 Apr 2025	sell	₹ 67.50	2.98 lac	₹ 2.01 cr
UNICO GLOBAL OPPORTUNITIES FUND LIMITED	03 Apr 2025	sell	₹ 68.00	41.28 lac	₹ 28.07 cr

Corporate Actions

History of Balaxi Pharmaceuticals Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Stock Split1 : 5
Ex-date: 30th May 2024Announced on: 28th Feb 2024
Nominal value change from INR 10 to INR 2.
Dividend₹ 0.50/share
Record date: 4th Jul 2022Ex-date: 1st Jul 2022
Announced on: 23rd May 2022

Company Profile

Overview of Balaxi Pharmaceuticals Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Balaxi Pharmaceuticals Limited is an India-based company. The Company operates as an intellectual property right (IPR)-based pharmaceutical company. The Company primarily operates in frontier markets across the Americas, Africa and the Caribbean islands. The Company is focusing on frontier markets, ...

Key personnel

Mr. Amol Mantri

Chief Financial Officer

Mr. Pranav Maheshwari

Senior Vice President - Business Development

Mr. Mohith Kumar Khandelwal

Compliance Officer, Company Secretary

Mr. Jignesh Dinesh Kumar Shah

Finance Controller, Angola

Mr. Ram Chawla

Country Head, Angola

Mr. Bharat Jawarani

Sales Head, Dominican Republic

Mr. Manish Jumnani

Sales Head, Guatemala

Mr. Karan Kapoor

Head - Operations, Dominican Republic

View all

Incorporated on

28 Sep 1942

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

IPO date

30 Nov 2015

Free Float

Website

https://balaxipharma.in/

Phone no.

+914023555300

Address

Plot No.409, H. No: 8-2-293, MAPS Towers, 3rd Floor, Phase-III, Road No: 81, Jubilee Hills, HYDERABAD, 500096, India

Frequently Asked Questions

What is the current share price of Balaxi Pharmaceuticals Ltd.?

The current share price of Balaxi Pharmaceuticals Ltd. is ₹ 22.77 as of 5 Oct 2026.

What is the market capitalisation of Balaxi Pharmaceuticals Ltd.?

The market capitalisation of Balaxi Pharmaceuticals Ltd. stands at ₹ 125.71 Cr.

What is the PE ratio of Balaxi Pharmaceuticals Ltd.?

The Price-to-Earnings (PE) ratio of Balaxi Pharmaceuticals Ltd. is 51.86 as of the latest trailing twelve months data.

What is the ROE and ROCE of Balaxi Pharmaceuticals Ltd.?

Balaxi Pharmaceuticals Ltd. has a Return on Equity (ROE) of 0.59% and a Return on Capital Employed (ROCE) of 2.15% as per the latest financial reports.

What is the 52-week high and low of Balaxi Pharmaceuticals Ltd.?

The 52-week high of Balaxi Pharmaceuticals Ltd. is - and the 52-week low is -.

What is the dividend yield of Balaxi Pharmaceuticals Ltd.?

The dividend yield of Balaxi Pharmaceuticals Ltd. is 0.00% based on the current market price.

What is the FII and DII holding in Balaxi Pharmaceuticals Ltd.?

Foreign Institutional Investors (FII) hold 0.00%, Domestic Institutional Investors (DII) hold 0.02% and retail/public investors hold 30.68% of Balaxi Pharmaceuticals Ltd. shares.

What sector does Balaxi Pharmaceuticals Ltd. belong to?

Balaxi Pharmaceuticals Ltd. operates in the Healthcare sector.

What is the beta of Balaxi Pharmaceuticals Ltd.?

The beta of Balaxi Pharmaceuticals Ltd. is 0.87, indicating its price volatility relative to the broader market. Over the past 1 year, Balaxi Pharmaceuticals Ltd. has delivered an absolute return of -48.14%.

What is the RSI of Balaxi Pharmaceuticals Ltd.?

The 14-day Relative Strength Index (RSI) of Balaxi Pharmaceuticals Ltd. is 45.99, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.

Balaxi Pharmaceuticals Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Balaxi Pharmaceuticals Ltd. Shareholding Pattern

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Corporate Actions

Company Profile